It has been reported that, in response to anti-VEGF therapies, some tumors can increase FGF secretion to stimulate endothelial cell proliferation, promote tumor angiogenesis, and bypass VEGF signaling pathways. The gene discussed is VEGFA; the disease is neoplasm.